728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

US Dermatologists Delighted with Sanofi/Regeneron's Dupixent, but Increased Familiarity and Experience with Pfizer's Eucrisa May be Breeding Contempt

THIS POST WAS ORIGINALLY PUBLISHED ON THIS SITE Click Here To Read Entire Article

EXTON, Pa., Nov. 30, 2017 /PRNewswire/ — The most recent release of RealTime Dynamix™: Atopic Dermatitis reveals steady uptake of the newest atopic dermatitis launches, Dupixent and Eucrisa.  Both agents have consistently enjoyed substantial user- and patient-base gains quarter over quarter since launching, with the vast majority of collaborating dermatologists reporting current clinical experience.  Furthermore, projected use is also favorable for both brands.

Despite widespread use and continued positive projections, dermatologists’ perceptions of Eucrisa are not so rosy.  Eucrisa garners the lowest satisfaction ratings among all approved atopic dermatitis treatments, with only one in ten citing that they are very satisfied with the topical PDE4 inhibitor.  Additionally, as familiarity with the brand has significantly increased over the year, the percentage of dermatologists who view Eucrisa as an advance over other topicals has significantly declined.  However, the majority of respondents have had at least some exposure to a Pfizer representative for Eucrisa and generally speaking, the representatives are rated as performing very well in all areas. Furthermore, Eucrisa’s direct to consumer (DTC) campaign is generally well-received among dermatologists and roughly one-third of respondents note that they have seen an increase in patient requests for Eucrisa since the launch of Pfizer’s DTC campaign—an important factor given that nearly two-thirds of patient inquiries for the brand resulted in a Eucrisa prescription.

On the other end of the spectrum, dermatologists are significantly more satisfied with Dupixent, the only approved biologic for atopic dermatitis, than they are with more traditional pharmacologic treatments such as topical steroids, topical calcineurin inhibitors, immunomodulators, or Eucrisa. Familiarity among dermatologists is significantly on the rise and is a decreasing barrier for use of the biologic.  Consistent with prior quarters, the vast majority of respondents continue to view Dupixent as a significant advance over other treatment options for atopic dermatitis, and the majority also report that they are extremely comfortable with Dupixent as a treatment for their adult atopic dermatitis patients.  Though nearly one out of five respondents have yet to see a Dupixent sales representative, those who have rate the representative as performing very well across all metrics, but especially with regard to their knowledge of Dupixent.  Barriers for adoption and increased use of the brand come in the form of the common insurance and out of pocket cost hurdles, issues that are unlikely to dissipate anytime in the near future. 

Though the atopic dermatitis pipeline

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *